Overall, these results provide compelling evidence that targeting SIRPα in CAR-modified macrophages not only augments their antitumor efficacy but also fosters a more robust immune response through T-cell recruitment in the tumor microenvironment. The gene discussed is SIRPA; the disease is neoplasm.